Stifel Nicolaus Issues Pessimistic Forecast for Inogen (NASDAQ:INGN) Stock Price

Inogen (NASDAQ:INGN) had its price target reduced by equities research analysts at Stifel Nicolaus from $10.00 to $7.00 in a report issued on Thursday,Benzinga reports. The firm presently has a “hold” rating on the medical technology company’s stock. Stifel Nicolaus’ price target points to a potential upside of 12.18% from the company’s current price.

A number of other analysts have also recently commented on the company. Needham & Company LLC restated a “hold” rating on shares of Inogen in a research report on Wednesday, April 9th. StockNews.com downgraded shares of Inogen from a “buy” rating to a “hold” rating in a research report on Wednesday, February 26th.

Inogen Stock Down 1.7 %

Shares of NASDAQ INGN opened at $6.24 on Thursday. The business’s 50 day moving average price is $7.17 and its 200 day moving average price is $8.91. The firm has a market cap of $167.77 million, a P/E ratio of -2.77 and a beta of 1.63. Inogen has a 52 week low of $5.75 and a 52 week high of $13.33.

Inogen (NASDAQ:INGN) last posted its earnings results on Wednesday, May 7th. The medical technology company reported ($0.25) EPS for the quarter, topping the consensus estimate of ($0.52) by $0.27. The firm had revenue of $82.28 million for the quarter, compared to analyst estimates of $79.57 million. Inogen had a negative return on equity of 27.38% and a negative net margin of 15.89%. As a group, research analysts expect that Inogen will post -1.73 earnings per share for the current year.

Institutional Investors Weigh In On Inogen

Several institutional investors and hedge funds have recently added to or reduced their stakes in the business. AlphaQuest LLC acquired a new stake in Inogen in the 4th quarter valued at about $43,000. Meeder Asset Management Inc. acquired a new stake in Inogen during the fourth quarter worth about $56,000. Integrated Quantitative Investments LLC acquired a new position in Inogen in the fourth quarter valued at approximately $92,000. Ieq Capital LLC acquired a new position in Inogen in the fourth quarter valued at about $94,000. Finally, Intech Investment Management LLC acquired a new position in shares of Inogen in the 4th quarter worth approximately $94,000. Institutional investors and hedge funds own 89.94% of the company’s stock.

About Inogen

Inogen, Inc, a medical technology company, develops, manufactures, and markets portable oxygen concentrators to patients, physicians and other clinicians, and third-party payors in the United States and internationally. Its oxygen concentrators are used to deliver supplemental long-term oxygen therapy to patients suffering from chronic respiratory conditions.